{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:50:59Z","timestamp":1790351459681,"version":"4.1.0"},"publisher-location":"Cham","reference-count":139,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783031400469","type":"print"},{"value":"9783031400476","type":"electronic"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1007\/164_2023_639","type":"book-chapter","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T19:03:58Z","timestamp":1678215838000},"page":"65-83","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia"],"prefix":"10.1007","author":[{"given":"Meike","family":"Kaehler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingolf","family":"Cascorbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,8]]},"reference":[{"issue":"9","key":"639_CR1","doi-asserted-by":"crossref","first-page":"13848","DOI":"10.3390\/molecules190913848","volume":"19","author":"N Anreddy","year":"2014","unstructured":"Anreddy N et al (2014) Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance. Molecules 19(9):13848\u201313877","journal-title":"Molecules"},{"issue":"12","key":"639_CR2","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.3324\/haematol.2019.242891","volume":"105","author":"E Atallah","year":"2020","unstructured":"Atallah E, Schiffer CA (2020) Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom? Haematologica 105(12):2738\u20132745","journal-title":"Haematologica"},{"issue":"6","key":"639_CR3","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00228-016-2038-9","volume":"72","author":"F Atiq","year":"2016","unstructured":"Atiq F et al (2016) A clinically relevant pharmacokinetic interaction between cyclosporine and imatinib. Eur J Clin Pharmacol 72(6):719\u2013723","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"639_CR4","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872\u2013884","journal-title":"Blood"},{"issue":"19","key":"639_CR5","doi-asserted-by":"crossref","first-page":"8912","DOI":"10.1158\/0008-5472.CAN-05-0076","volume":"65","author":"DJ Barnes","year":"2005","unstructured":"Barnes DJ et al (2005) Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res 65(19):8912\u20138919","journal-title":"Cancer Res"},{"issue":"4","key":"639_CR6","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1179\/1607845412Y.0000000067","volume":"18","author":"AM Bedewy","year":"2013","unstructured":"Bedewy AM, El-Maghraby SM (2013) Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy? Hematology 18(4):211\u2013216","journal-title":"Hematology"},{"key":"639_CR7","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ejmech.2017.07.062","volume":"142","author":"GL Beretta","year":"2017","unstructured":"Beretta GL et al (2017) Overcoming ABC transporter-mediated multidrug resistance: the dual role of tyrosine kinase inhibitors as multitargeting agents. Eur J Med Chem 142:271\u2013289","journal-title":"Eur J Med Chem"},{"issue":"1","key":"639_CR8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/leu.2010.238","volume":"25","author":"D Bixby","year":"2011","unstructured":"Bixby D, Talpaz M (2011) Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia 25(1):7\u201322","journal-title":"Leukemia"},{"issue":"4","key":"639_CR9","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","volume":"37","author":"TP Braun","year":"2020","unstructured":"Braun TP, Eide CA, Druker BJ (2020) Response and resistance to BCR-ABL1-targeted therapies. Cancer Cell 37(4):530\u2013542","journal-title":"Cancer Cell"},{"issue":"8","key":"639_CR10","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1080\/13543784.2021.1941863","volume":"30","author":"M Breccia","year":"2021","unstructured":"Breccia M et al (2021) Asciminib: an investigational agent for the treatment of chronic myeloid leukemia. Expert Opin Investig Drugs 30(8):803\u2013811","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"639_CR11","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/sj.leu.2404638","volume":"21","author":"C Brendel","year":"2007","unstructured":"Brendel C et al (2007) Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 21(6):1267\u20131275","journal-title":"Leukemia"},{"key":"639_CR12","doi-asserted-by":"crossref","unstructured":"Bruckmueller H, Cascorbi I (2021) ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding? Expert Opin Drug Metab Toxicol:1\u201328","DOI":"10.1080\/17425255.2021.1876661"},{"issue":"7","key":"639_CR13","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1073\/pnas.92.7.2558","volume":"92","author":"E Buchdunger","year":"1995","unstructured":"Buchdunger E et al (1995) Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci U S A 92(7):2558\u20132562","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"639_CR14","first-page":"100","volume":"56","author":"E Buchdunger","year":"1996","unstructured":"Buchdunger E et al (1996) Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56(1):100\u2013104","journal-title":"Cancer Res"},{"key":"639_CR15","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejca.2017.02.028","volume":"77","author":"L Campiotti","year":"2017","unstructured":"Campiotti L et al (2017) Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: a systematic review and a meta-analysis. Eur J Cancer 77:48\u201356","journal-title":"Eur J Cancer"},{"key":"639_CR16","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.phrs.2018.02.005","volume":"131","author":"S Cargnin","year":"2018","unstructured":"Cargnin S et al (2018) Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: a systematic review and meta-analysis. Pharmacol Res 131:244\u2013254","journal-title":"Pharmacol Res"},{"issue":"1","key":"639_CR17","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1186\/s12885-018-5167-y","volume":"18","author":"N Cerveira","year":"2018","unstructured":"Cerveira N et al (2018) Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution. BMC Cancer 18(1):1245","journal-title":"BMC Cancer"},{"issue":"9","key":"639_CR18","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/sj.leu.2404310","volume":"20","author":"YJ Chung","year":"2006","unstructured":"Chung YJ et al (2006) Gene expression signatures associated with the resistance to imatinib. Leukemia 20(9):1542\u20131550","journal-title":"Leukemia"},{"issue":"4","key":"639_CR19","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1158\/1078-0432.CCR-10-1613","volume":"18","author":"D Cilloni","year":"2012","unstructured":"Cilloni D, Saglio G (2012) Molecular pathways: BCR-ABL. Clin Cancer Res 18(4):930\u2013937","journal-title":"Clin Cancer Res"},{"issue":"20","key":"639_CR20","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE et al (2016) Final 5-year study results of DASISION: the Dasatinib versus imatinib study in treatment-naive chronic myeloid Leukemia patients trial. J Clin Oncol 34(20):2333\u20132340","journal-title":"J Clin Oncol"},{"issue":"11","key":"639_CR21","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/leu.2009.166","volume":"23","author":"A Davies","year":"2009","unstructured":"Davies A et al (2009) Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia 23(11):1999\u20132006","journal-title":"Leukemia"},{"issue":"3","key":"639_CR22","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s12032-014-0851-5","volume":"31","author":"LT de Lima","year":"2014","unstructured":"de Lima LT et al (2014) Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia. Med Oncol 31(3):851","journal-title":"Med Oncol"},{"issue":"9","key":"639_CR23","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1007\/s11095-014-1389-0","volume":"31","author":"J Deng","year":"2014","unstructured":"Deng J et al (2014) ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors. Pharm Res 31(9):2237\u20132255","journal-title":"Pharm Res"},{"key":"639_CR24","doi-asserted-by":"crossref","first-page":"29559","DOI":"10.1038\/srep29559","volume":"6","author":"G Dessilly","year":"2016","unstructured":"Dessilly G et al (2016) Impact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib. Sci Rep 6:29559","journal-title":"Sci Rep"},{"issue":"8","key":"639_CR25","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1182\/blood-2004-10-3967","volume":"105","author":"AL Dewar","year":"2005","unstructured":"Dewar AL et al (2005) Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 105(8):3127\u20133132","journal-title":"Blood"},{"issue":"9","key":"639_CR26","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2165\/11593320-000000000-00000","volume":"50","author":"P Di Gion","year":"2011","unstructured":"Di Gion P et al (2011) Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. Clin Pharmacokinet 50(9):551\u2013603","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"639_CR27","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1124\/dmd.109.031302","volume":"38","author":"M Dohse","year":"2010","unstructured":"Dohse M et al (2010) Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos 38(8):1371\u20131380","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"639_CR28","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ et al (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2(5):561\u2013566","journal-title":"Nat Med"},{"issue":"4","key":"639_CR29","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00280-004-0832-z","volume":"54","author":"C Dutreix","year":"2004","unstructured":"Dutreix C et al (2004) Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol 54(4):290\u2013294","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"639_CR30","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3109\/10428194.2012.715345","volume":"54","author":"LN Eadie","year":"2013","unstructured":"Eadie LN et al (2013) Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2. Leuk Lymphoma 54(3):569\u2013578","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"639_CR31","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ccell.2019.08.004","volume":"36","author":"CA Eide","year":"2019","unstructured":"Eide CA et al (2019) Combining the allosteric inhibitor Asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants. Cancer Cell 36(4):431\u2013443 e5","journal-title":"Cancer Cell"},{"issue":"9","key":"639_CR32","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1186\/s13059-014-0461-8","volume":"15","author":"AM Eiring","year":"2014","unstructured":"Eiring AM, Deininger MW (2014) Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia. Genome Biol 15(9):461","journal-title":"Genome Biol"},{"issue":"4","key":"639_CR33","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/leu.2010.16","volume":"24","author":"JR Engler","year":"2010","unstructured":"Engler JR et al (2010) Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity. Leukemia 24(4):765\u2013770","journal-title":"Leukemia"},{"issue":"3","key":"639_CR34","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","volume":"35","author":"G Etienne","year":"2017","unstructured":"Etienne G et al (2017) Long-term follow-up of the French stop imatinib (STIM1) study in patients with chronic myeloid Leukemia. J Clin Oncol 35(3):298\u2013305","journal-title":"J Clin Oncol"},{"issue":"8","key":"639_CR35","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1111\/j.1476-5381.2011.01732.x","volume":"165","author":"AM Filppula","year":"2012","unstructured":"Filppula AM et al (2012) Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol 165(8):2787\u20132798","journal-title":"Br J Pharmacol"},{"key":"639_CR36","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1741-7015-10-23","volume":"10","author":"L Finn","year":"2012","unstructured":"Finn L, Markovic SN, Joseph RW (2012) Therapy for metastatic melanoma: the past, present, and future. BMC Med 10:23","journal-title":"BMC Med"},{"issue":"8","key":"639_CR37","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3324\/haematol.2009.020636","volume":"95","author":"S Flamant","year":"2010","unstructured":"Flamant S et al (2010) Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia. Haematologica 95(8):1325\u20131333","journal-title":"Haematologica"},{"issue":"3","key":"639_CR38","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11912-018-0676-z","volume":"20","author":"M Furue","year":"2018","unstructured":"Furue M et al (2018) Melanoma and immune checkpoint inhibitors. Curr Oncol Rep 20(3):29","journal-title":"Curr Oncol Rep"},{"issue":"50","key":"639_CR39","doi-asserted-by":"crossref","first-page":"88021","DOI":"10.18632\/oncotarget.21406","volume":"8","author":"S Galimberti","year":"2017","unstructured":"Galimberti S et al (2017) The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia. Oncotarget 8(50):88021\u201388033","journal-title":"Oncotarget"},{"issue":"2","key":"639_CR40","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s12032-013-0522-y","volume":"30","author":"J Gao","year":"2013","unstructured":"Gao J et al (2013) Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors. Med Oncol 30(2):522","journal-title":"Med Oncol"},{"issue":"2","key":"639_CR41","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.clpt.2006.05.003","volume":"80","author":"ER Gardner","year":"2006","unstructured":"Gardner ER et al (2006) Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol Ther 80(2):192\u2013201","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"639_CR42","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/leu.2009.111","volume":"23","author":"FJ Giles","year":"2009","unstructured":"Giles FJ, O'Dwyer M, Swords R (2009) Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 23(10):1698\u20131707","journal-title":"Leukemia"},{"issue":"5531","key":"639_CR43","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME et al (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293(5531):876\u2013880","journal-title":"Science"},{"issue":"4","key":"639_CR44","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00228-009-0772-y","volume":"66","author":"H Green","year":"2010","unstructured":"Green H et al (2010) CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity. Eur J Clin Pharmacol 66(4):383\u2013386","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"639_CR45","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ccr.2010.04.025","volume":"18","author":"MA Gregory","year":"2010","unstructured":"Gregory MA et al (2010) Wnt\/Ca2+\/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer Cell 18(1):74\u201387","journal-title":"Cancer Cell"},{"issue":"10","key":"639_CR46","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.3109\/10428194.2011.584005","volume":"52","author":"M Gromicho","year":"2011","unstructured":"Gromicho M et al (2011) Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1. Leuk Lymphoma 52(10):1980\u20131990","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"639_CR47","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1182\/blood-2010-07-294330","volume":"117","author":"A Haouala","year":"2011","unstructured":"Haouala A et al (2011) Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood 117(8):e75\u2013e87","journal-title":"Blood"},{"key":"639_CR48","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.phrs.2017.03.011","volume":"120","author":"N Harivenkatesh","year":"2017","unstructured":"Harivenkatesh N et al (2017) Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia. Pharmacol Res 120:138\u2013145","journal-title":"Pharmacol Res"},{"issue":"4","key":"639_CR49","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1476-5381.2009.00383.x","volume":"158","author":"C Hegedus","year":"2009","unstructured":"Hegedus C et al (2009) Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol 158(4):1153\u20131164","journal-title":"Br J Pharmacol"},{"issue":"3","key":"639_CR50","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V96.3.925","volume":"96","author":"MC Heinrich","year":"2000","unstructured":"Heinrich MC et al (2000) Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96(3):925\u2013932","journal-title":"Blood"},{"issue":"5940","key":"639_CR51","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/306239a0","volume":"306","author":"N Heisterkamp","year":"1983","unstructured":"Heisterkamp N et al (1983) Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature 306(5940):239\u2013242","journal-title":"Nature"},{"issue":"9","key":"639_CR52","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2016.143","volume":"30","author":"G Heller","year":"2016","unstructured":"Heller G et al (2016) Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia. Leukemia 30(9):1861\u20131868","journal-title":"Leukemia"},{"key":"639_CR53","doi-asserted-by":"crossref","unstructured":"Hershkovitz-Rokah O et al (2014) MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein. Cancer Lett","DOI":"10.1016\/j.canlet.2014.10.006"},{"issue":"10","key":"639_CR54","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A et al (2017) Long-term outcomes of imatinib treatment for chronic myeloid Leukemia. N Engl J Med 376(10):917\u2013927","journal-title":"N Engl J Med"},{"issue":"4","key":"639_CR55","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A et al (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34(4):966\u2013984","journal-title":"Leukemia"},{"issue":"1","key":"639_CR56","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"108","author":"T Hughes","year":"2006","unstructured":"Hughes T et al (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108(1):28\u201337","journal-title":"Blood"},{"issue":"24","key":"639_CR57","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","volume":"381","author":"TP Hughes","year":"2019","unstructured":"Hughes TP et al (2019a) Asciminib in chronic myeloid Leukemia after ABL kinase inhibitor failure. N Engl J Med 381(24):2315\u20132326","journal-title":"N Engl J Med"},{"issue":"Supplement_1","key":"639_CR58","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1182\/blood-2019-128761","volume":"134","author":"T Hughes","year":"2019","unstructured":"Hughes T et al (2019b) Long-term outcomes in patients with chronic myeloid Leukemia in chronic phase receiving frontline nilotinib versus imatinib: Enestnd 10-year analysis. Blood 134(Supplement_1):2924","journal-title":"Blood"},{"issue":"1","key":"639_CR59","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3109\/02841868309134332","volume":"22","author":"S Hukku","year":"1983","unstructured":"Hukku S et al (1983) Splenic irradiation in chronic myeloid leukemia. Acta Radiol Oncol 22(1):9\u201312","journal-title":"Acta Radiol Oncol"},{"issue":"5","key":"639_CR60","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.hoc.2011.09.004","volume":"25","author":"E Jabbour","year":"2011","unstructured":"Jabbour E et al (2011) Chronic myeloid leukemia: mechanisms of resistance and treatment. Hematol Oncol Clin North Am 25(5):981\u2013995. v","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"639_CR61","first-page":"1710052","volume":"9","author":"DL Jardim","year":"2020","unstructured":"Jardim DL et al (2020) Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds. Onco Targets Ther 9(1):1710052","journal-title":"Onco Targets Ther"},{"issue":"7","key":"639_CR62","doi-asserted-by":"crossref","first-page":"e22110","DOI":"10.1371\/journal.pone.0022110","volume":"6","author":"J Jelinek","year":"2011","unstructured":"Jelinek J et al (2011) Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia. PLoS One 6(7):e22110","journal-title":"PLoS One"},{"issue":"1","key":"639_CR63","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12943-018-0801-5","volume":"17","author":"Q Jiao","year":"2018","unstructured":"Jiao Q et al (2018) Advances in studies of tyrosine kinase inhibitors and their acquired resistance. Mol Cancer 17(1):36","journal-title":"Mol Cancer"},{"issue":"4","key":"639_CR64","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1182\/blood-2006-02-003145","volume":"108","author":"NE Jordanides","year":"2006","unstructured":"Jordanides NE et al (2006) Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood 108(4):1370\u20131373","journal-title":"Blood"},{"issue":"54","key":"639_CR65","doi-asserted-by":"crossref","first-page":"92018","DOI":"10.18632\/oncotarget.21272","volume":"8","author":"M Kaehler","year":"2017","unstructured":"Kaehler M et al (2017) MicroRNA-212\/ABCG2-axis contributes to development of imatinib-resistance in leukemic cells. Oncotarget 8(54):92018\u201392031","journal-title":"Oncotarget"},{"key":"639_CR66","doi-asserted-by":"crossref","unstructured":"Kaehler M et al (2022) Genome-wide expression and methylation analyses reveal aberrant cell adhesion signaling in tyrosine kinase inhibitor-resistant CML cells. Oncol Rep 48(2)","DOI":"10.3892\/or.2022.8355"},{"issue":"5","key":"639_CR67","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2015.36","volume":"29","author":"L Kalmanti","year":"2015","unstructured":"Kalmanti L et al (2015) Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia 29(5):1123\u20131132","journal-title":"Leukemia"},{"issue":"3","key":"639_CR68","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0002-9343(87)90754-6","volume":"83","author":"HM Kantarjian","year":"1987","unstructured":"Kantarjian HM et al (1987) Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med 83(3):445\u2013454","journal-title":"Am J Med"},{"issue":"4","key":"639_CR69","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/1097-0142(197204)29:4<1052::AID-CNCR2820290454>3.0.CO;2-7","volume":"29","author":"BJ Kennedy","year":"1972","unstructured":"Kennedy BJ (1972) Hydroxyurea therapy in chronic myelogenous leukemia. Cancer 29(4):1052\u20131056","journal-title":"Cancer"},{"issue":"14","key":"639_CR70","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1158\/1078-0432.CCR-09-0145","volume":"15","author":"DH Kim","year":"2009","unstructured":"Kim DH et al (2009) Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res 15(14):4750\u20134758","journal-title":"Clin Cancer Res"},{"issue":"8","key":"639_CR71","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1038\/bcj.2011.32","volume":"1","author":"TM Kim","year":"2011","unstructured":"Kim TM et al (2011) Gene expression signatures associated with the in vitro resistance to two tyrosine kinase inhibitors, nilotinib and imatinib. Blood Cancer J 1(8):e32","journal-title":"Blood Cancer J"},{"key":"639_CR72","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.leukres.2017.06.009","volume":"59","author":"T Kim","year":"2017","unstructured":"Kim T et al (2017) Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy. Leuk Res 59:142\u2013148","journal-title":"Leuk Res"},{"issue":"2","key":"639_CR73","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/gtc.12022","volume":"18","author":"D Kitagawa","year":"2013","unstructured":"Kitagawa D et al (2013) Activity-based kinase profiling of approved tyrosine kinase inhibitors. Genes Cells 18(2):110\u2013122","journal-title":"Genes Cells"},{"key":"639_CR74","doi-asserted-by":"crossref","unstructured":"Klumper T et al (2020) Expression differences of miR-142-5p between treatment-naive chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance. Exp Hematol Oncol 9(1)","DOI":"10.1186\/s40164-020-00183-1"},{"issue":"1","key":"639_CR75","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/JTO.0b013e3182781e35","volume":"8","author":"S Kobayashi","year":"2013","unstructured":"Kobayashi S et al (2013) Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J Thorac Oncol 8(1):45\u201351","journal-title":"J Thorac Oncol"},{"issue":"Suppl","key":"639_CR76","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1038\/ng1799","volume":"38","author":"J Krutzfeldt","year":"2006","unstructured":"Krutzfeldt J, Poy MN, Stoffel M (2006) Strategies to determine the biological function of microRNAs. Nat Genet 38(Suppl):S14\u2013S19","journal-title":"Nat Genet"},{"issue":"4","key":"639_CR77","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","volume":"27","author":"P Kuehl","year":"2001","unstructured":"Kuehl P et al (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27(4):383\u2013391","journal-title":"Nat Genet"},{"issue":"4","key":"639_CR78","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s11010-022-04376-6","volume":"477","author":"V Kumar","year":"2022","unstructured":"Kumar V et al (2022) Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review. Mol Cell Biochem 477(4):1261\u20131279","journal-title":"Mol Cell Biochem"},{"issue":"2","key":"639_CR79","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1124\/jpet.117.246116","volume":"365","author":"JK Laramy","year":"2018","unstructured":"Laramy JK et al (2018) Pharmacokinetic assessment of cooperative efflux of the multitargeted kinase inhibitor ponatinib across the blood-brain barrier. J Pharmacol Exp Ther 365(2):249\u2013261","journal-title":"J Pharmacol Exp Ther"},{"key":"639_CR80","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drup.2016.05.001","volume":"27","author":"W Li","year":"2016","unstructured":"Li W et al (2016) Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies. Drug Resist Updat 27:14\u201329","journal-title":"Drug Resist Updat"},{"issue":"2","key":"639_CR81","first-page":"327","volume":"9","author":"TC Liu","year":"2002","unstructured":"Liu TC et al (2002) Polymorphism analysis of CYP3A5 in myeloid leukemia. Oncol Rep 9(2):327\u2013329","journal-title":"Oncol Rep"},{"issue":"2","key":"639_CR82","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.bbrc.2012.07.098","volume":"425","author":"L Liu","year":"2012","unstructured":"Liu L et al (2012) Myc induced miR-144\/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562. Biochem Biophys Res Commun 425(2):368\u2013373","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"639_CR83","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.leukres.2012.12.003","volume":"37","author":"Y Liu","year":"2013","unstructured":"Liu Y et al (2013) Decreased microRNA-30a levels are associated with enhanced ABL1 and BCR-ABL1 expression in chronic myeloid leukemia. Leuk Res 37(3):349\u2013356","journal-title":"Leuk Res"},{"issue":"21","key":"639_CR84","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch TJ et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129\u20132139","journal-title":"N Engl J Med"},{"issue":"1","key":"639_CR85","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11899-012-0152-z","volume":"8","author":"K Machova Polakova","year":"2013","unstructured":"Machova Polakova K, Koblihova J, Stopka T (2013) Role of epigenetics in chronic myeloid leukemia. Curr Hematol Malig Rep 8(1):28\u201336","journal-title":"Curr Hematol Malig Rep"},{"issue":"3","key":"639_CR86","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.bbapap.2009.11.008","volume":"1804","author":"PW Manley","year":"2010","unstructured":"Manley PW et al (2010) Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta 1804(3):445\u2013453","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"639_CR87","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/leu.2008.27","volume":"22","author":"JA McCubrey","year":"2008","unstructured":"McCubrey JA et al (2008) Targeting survival cascades induced by activation of Ras\/Raf\/MEK\/ERK, PI3K\/PTEN\/Akt\/mTOR and Jak\/STAT pathways for effective leukemia therapy. Leukemia 22(4):708\u2013722","journal-title":"Leukemia"},{"key":"639_CR88","doi-asserted-by":"crossref","unstructured":"Millot F et al (2021) Discontinuation of imatinib in children with chronic myeloid Leukemia: a study from the international registry of childhood CML. Cancers (Basel) 13(16)","DOI":"10.3390\/cancers13164102"},{"issue":"24","key":"639_CR89","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-09-1068","volume":"15","author":"D Milojkovic","year":"2009","unstructured":"Milojkovic D, Apperley J (2009) Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid Leukemia. Clin Cancer Res 15(24):7519\u20137527","journal-title":"Clin Cancer Res"},{"key":"639_CR90","doi-asserted-by":"crossref","unstructured":"Minciacchi VR, Kumar R, Krause DS (2021) Chronic myeloid Leukemia: a model disease of the past, present and future. Cell 10(1)","DOI":"10.3390\/cells10010117"},{"key":"639_CR91","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.biopha.2018.02.038","volume":"100","author":"IS Mohammad","year":"2018","unstructured":"Mohammad IS, He W, Yin L (2018) Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR. Biomed Pharmacother 100:335\u2013348","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"639_CR92","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1445-5994.1981.tb03534.x","volume":"11","author":"G Morstyn","year":"1981","unstructured":"Morstyn G et al (1981) Effects of high dose busulphan on leukaemic progenitor cells in chronic myeloid leukaemia. Aust NZ J Med 11(6):609\u2013614","journal-title":"Aust NZ J Med"},{"issue":"15","key":"639_CR93","first-page":"4236","volume":"62","author":"B Nagar","year":"2002","unstructured":"Nagar B et al (2002) Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 62(15):4236\u20134243","journal-title":"Cancer Res"},{"issue":"4","key":"639_CR94","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1158\/1078-0432.CCR-13-1999","volume":"20","author":"AT Nies","year":"2014","unstructured":"Nies AT et al (2014) Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1). Clin Cancer Res 20(4):985\u2013994","journal-title":"Clin Cancer Res"},{"key":"639_CR95","first-page":"85","volume":"25","author":"PC Nowell","year":"1960","unstructured":"Nowell PC, Hungerford DA (1960) Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 25:85\u2013109","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"639_CR96","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O'Brien","year":"2003","unstructured":"O'Brien SG et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348(11):994\u20131004","journal-title":"N Engl J Med"},{"issue":"5","key":"639_CR97","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O'Hare","year":"2009","unstructured":"O'Hare T et al (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16(5):401\u2013412","journal-title":"Cancer Cell"},{"issue":"8","key":"639_CR98","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc3317","volume":"12","author":"T O'Hare","year":"2012","unstructured":"O'Hare T et al (2012) Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer 12(8):513\u2013526","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"639_CR99","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1177\/1078155217743565","volume":"25","author":"S Osorio","year":"2019","unstructured":"Osorio S et al (2019) Inadequate response to imatinib treatment in chronic myeloid leukemia due to a drug interaction with phenytoin. J Oncol Pharm Pract 25(3):694\u2013698","journal-title":"J Oncol Pharm Pract"},{"issue":"7","key":"639_CR100","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","volume":"171","author":"AC Palmer","year":"2017","unstructured":"Palmer AC, Sorger PK (2017) Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy. Cell 171(7):1678\u20131691 e13","journal-title":"Cell"},{"issue":"4","key":"639_CR101","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.hoc.2017.04.007","volume":"31","author":"AB Patel","year":"2017","unstructured":"Patel AB, O'Hare T, Deininger MW (2017) Mechanisms of resistance to ABL kinase inhibition in chronic myeloid Leukemia and the development of next generation ABL kinase inhibitors. Hematol Oncol Clin North Am 31(4):589\u2013612","journal-title":"Hematol Oncol Clin North Am"},{"issue":"5","key":"639_CR102","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","volume":"22","author":"B Peng","year":"2004","unstructured":"Peng B et al (2004) Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol Off J Am Soc Clin Oncol 22(5):935\u2013942","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9","key":"639_CR103","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","volume":"44","author":"B Peng","year":"2005","unstructured":"Peng B, Lloyd P, Schran H (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44(9):879\u2013894","journal-title":"Clin Pharmacokinet"},{"key":"639_CR104","doi-asserted-by":"crossref","first-page":"175883591983351","DOI":"10.1177\/1758835919833519","volume":"11","author":"S Pernas","year":"2019","unstructured":"Pernas S, Tolaney SM (2019) HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. Ther Adv Med Oncol 11:1758835919833519","journal-title":"Ther Adv Med Oncol"},{"key":"639_CR105","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ctrv.2016.11.011","volume":"55","author":"A Poveda","year":"2017","unstructured":"Poveda A et al (2017) GEIS guidelines for gastrointestinal sarcomas (GIST). Cancer Treat Rev 55:107\u2013119","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"639_CR106","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0889-8588(05)70198-2","volume":"15","author":"JP Radich","year":"2001","unstructured":"Radich JP (2001) Philadelphia chromosome-positive acute lymphocytic leukemia. Hematol Oncol Clin North Am 15(1):21\u201336","journal-title":"Hematol Oncol Clin North Am"},{"issue":"5\u20136","key":"639_CR107","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/1947601912462126","volume":"3","author":"EP Reddy","year":"2012","unstructured":"Reddy EP, Aggarwal AK (2012) The ins and outs of bcr-abl inhibition. Genes Cancer 3(5\u20136):447\u2013454","journal-title":"Genes Cancer"},{"issue":"3","key":"639_CR108","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/leu.2008.334","volume":"23","author":"LL Remsing Rix","year":"2009","unstructured":"Remsing Rix LL et al (2009) Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 23(3):477\u2013485","journal-title":"Leukemia"},{"issue":"3","key":"639_CR109","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nrclinonc.2016.139","volume":"14","author":"G Rosti","year":"2017","unstructured":"Rosti G et al (2017) Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? Nat Rev Clin Oncol 14(3):141\u2013154","journal-title":"Nat Rev Clin Oncol"},{"issue":"5405","key":"639_CR110","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD (1973) Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243(5405):290\u2013293","journal-title":"Nature"},{"key":"639_CR111","doi-asserted-by":"crossref","unstructured":"Saiz-Rodriguez M et al (2020) Effect of the Most relevant CYP3A4 and CYP3A5 polymorphisms on the pharmacokinetic parameters of 10 CYP3A substrates. Biomedicine 8(4)","DOI":"10.3390\/biomedicines8040094"},{"key":"639_CR112","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1476-4598-8-69","volume":"8","author":"E San Jose-Eneriz","year":"2009","unstructured":"San Jose-Eneriz E et al (2009) MicroRNA expression profiling in imatinib-resistant chronic myeloid Leukemia patients without clinically significant ABL1-mutations. Mol Cancer 8:69","journal-title":"Mol Cancer"},{"issue":"1","key":"639_CR113","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1365-2141.1997.d01-1982.x","volume":"96","author":"DG Savage","year":"1997","unstructured":"Savage DG, Szydlo RM, Goldman JM (1997) Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period. Br J Haematol 96(1):111\u2013116","journal-title":"Br J Haematol"},{"issue":"17","key":"639_CR114","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","volume":"340","author":"CL Sawyers","year":"1999","unstructured":"Sawyers CL (1999) Chronic myeloid leukemia. N Engl J Med 340(17):1330\u20131340","journal-title":"N Engl J Med"},{"issue":"18","key":"639_CR115","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","volume":"61","author":"J Schoepfer","year":"2018","unstructured":"Schoepfer J et al (2018) Discovery of Asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1. J Med Chem 61(18):8120\u20138135","journal-title":"J Med Chem"},{"issue":"9","key":"639_CR116","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1158\/1535-7163.MCT-12-0302","volume":"11","author":"R Sen","year":"2012","unstructured":"Sen R et al (2012) The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2. Mol Cancer Ther 11(9):2033\u20132044","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"639_CR117","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/annonc\/mds532","volume":"24","author":"SJ Seong","year":"2013","unstructured":"Seong SJ et al (2013) Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients. Ann Oncol 24(3):756\u2013760","journal-title":"Ann Oncol"},{"issue":"9","key":"639_CR118","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","volume":"117","author":"NP Shah","year":"2007","unstructured":"Shah NP et al (2007) Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 117(9):2562\u20132569","journal-title":"J Clin Invest"},{"issue":"10","key":"639_CR119","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.leukres.2013.07.019","volume":"37","author":"T Shibuta","year":"2013","unstructured":"Shibuta T et al (2013) Imatinib induces demethylation of miR-203 gene: an epigenetic mechanism of anti-tumor effect of imatinib. Leuk Res 37(10):1278\u20131286","journal-title":"Leuk Res"},{"issue":"1","key":"639_CR120","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/FPC.0000000000000022","volume":"24","author":"K Skoglund","year":"2014","unstructured":"Skoglund K et al (2014) Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line. Pharmacogenet Genomics 24(1):52\u201361","journal-title":"Pharmacogenet Genomics"},{"issue":"7","key":"639_CR121","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/cncr.28522","volume":"120","author":"S Soverini","year":"2014","unstructured":"Soverini S et al (2014) Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: the main changes are in the type of mutations, but not in the frequency of mutation involvement. Cancer 120(7):1002\u20131009","journal-title":"Cancer"},{"issue":"1","key":"639_CR122","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13045-019-0729-2","volume":"12","author":"S Soverini","year":"2019","unstructured":"Soverini S, Bassan R, Lion T (2019) Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges. J Hematol Oncol 12(1):39","journal-title":"J Hematol Oncol"},{"issue":"8","key":"639_CR123","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","volume":"30","author":"JL Steegmann","year":"2016","unstructured":"Steegmann JL et al (2016) European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 30(8):1648\u20131671","journal-title":"Leukemia"},{"issue":"6","key":"639_CR124","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2174\/1389200221666200620210522","volume":"21","author":"S Sudsakorn","year":"2020","unstructured":"Sudsakorn S et al (2020) 2020 FDA drug-drug interaction guidance: a comparison analysis and action plan by pharmaceutical industrial scientists. Curr Drug Metab 21(6):403\u2013426","journal-title":"Curr Drug Metab"},{"issue":"8","key":"639_CR125","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","volume":"372","author":"SM Swain","year":"2015","unstructured":"Swain SM et al (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372(8):724\u2013734","journal-title":"N Engl J Med"},{"key":"639_CR126","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1200\/GO.21.00058","volume":"7","author":"F Tadesse","year":"2021","unstructured":"Tadesse F et al (2021) Spectrum of BCR-ABL mutations and treatment outcomes in Ethiopian imatinib-resistant patients with chronic myeloid Leukemia. JCO Glob Oncol 7:1187\u20131193","journal-title":"JCO Glob Oncol"},{"issue":"6","key":"639_CR127","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/clpt.2010.186","volume":"88","author":"N Takahashi","year":"2010","unstructured":"Takahashi N et al (2010) Correlation between imatinib pharmacokinetics and clinical response in Japanese patients with chronic-phase chronic myeloid leukemia. Clin Pharmacol Ther 88(6):809\u2013813","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"639_CR128","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-2141.1986.tb07576.x","volume":"64","author":"M Talpaz","year":"1986","unstructured":"Talpaz M et al (1986) Chronic myelogenous leukaemia: haematological remissions with alpha interferon. Br J Haematol 64(1):87\u201395","journal-title":"Br J Haematol"},{"issue":"5","key":"639_CR129","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1182\/blood.V69.5.1280.1280","volume":"69","author":"M Talpaz","year":"1987","unstructured":"Talpaz M et al (1987) Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 69(5):1280\u20131288","journal-title":"Blood"},{"issue":"12","key":"639_CR130","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/jcph.1312","volume":"58","author":"X Tian","year":"2018","unstructured":"Tian X et al (2018) Clinical pharmacokinetic and pharmacodynamic overview of nilotinib, a selective tyrosine kinase inhibitor. J Clin Pharmacol 58(12):1533\u20131540","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"639_CR131","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/FPC.0b013e328350012b","volume":"22","author":"E Turrini","year":"2012","unstructured":"Turrini E et al (2012) MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression. Pharmacogenet Genomics 22(3):198\u2013205","journal-title":"Pharmacogenet Genomics"},{"issue":"10","key":"639_CR132","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3324\/haematol.2019.222059","volume":"104","author":"P Valent","year":"2019","unstructured":"Valent P et al (2019) Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. Haematologica 104(10):1935\u20131949","journal-title":"Haematologica"},{"issue":"3","key":"639_CR133","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.drup.2008.03.002","volume":"11","author":"RH van Schaik","year":"2008","unstructured":"van Schaik RH (2008) CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist Updat 11(3):77\u201398","journal-title":"Drug Resist Updat"},{"issue":"4","key":"639_CR134","doi-asserted-by":"crossref","first-page":"14967","DOI":"10.4238\/2015.November.24.4","volume":"14","author":"JL Wang","year":"2015","unstructured":"Wang JL et al (2015) Multidrug resistance gene (MDR1) polymorphisms may not be directly associated with response to imatinib in chronic myeloid leukemia. Genet Mol Res 14(4):14967\u201314978","journal-title":"Genet Mol Res"},{"issue":"10","key":"639_CR135","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/leu.2015.170","volume":"29","author":"DB Watkins","year":"2015","unstructured":"Watkins DB, Hughes TP, White DL (2015) OCT1 and imatinib transport in CML: is it clinically relevant? Leukemia 29(10):1960\u20131969","journal-title":"Leukemia"},{"issue":"3","key":"639_CR136","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/clpt.2014.129","volume":"96","author":"AN Werk","year":"2014","unstructured":"Werk AN, Cascorbi I (2014) Functional gene variants of CYP3A4. Clin Pharmacol Ther 96(3):340\u2013348","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"639_CR137","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","volume":"108","author":"DL White","year":"2006","unstructured":"White DL et al (2006) OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108(2):697\u2013704","journal-title":"Blood"},{"issue":"8","key":"639_CR138","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1248\/bpb.b14-00254","volume":"37","author":"Y Yamakawa","year":"2014","unstructured":"Yamakawa Y et al (2014) Distinct interaction of nilotinib and imatinib with P-glycoprotein in intracellular accumulation and cytotoxicity in CML cell line K562 cells. Biol Pharm Bull 37(8):1330\u20131335","journal-title":"Biol Pharm Bull"},{"key":"639_CR139","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40364-019-0179-6","volume":"7","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Yang S, Wang Q (2019) Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer. Biomark Res 7:27","journal-title":"Biomark Res"}],"container-title":["Handbook of Experimental Pharmacology","Precision Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2023_639","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T12:04:32Z","timestamp":1693569872000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/164_2023_639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9783031400469","9783031400476"],"references-count":139,"URL":"https:\/\/doi.org\/10.1007\/164_2023_639","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"8 March 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}